Smart drug cycling tested for tough skin cancer

This early pilot study is testing whether using a flexible on-and-off schedule for three cancer drugs works better for people with advanced melanoma that has a specific BRAF gene mutation. The drugs combine targeted therapy (encorafenib and binimetinib) that blocks cancer cell growth with immunotherapy (nivolumab) that helps the immune system fight cancer. Researchers want to see if this adaptive approach helps patients stay on treatment longer without their cancer getting worse.